CSIRO and Mirus Bio LLC are pleased to announce a new license arrangement that will enable Mirus Bio to utilize the unique characteristics of CSIRO's Reversible Addition-Fragmentation chain Transfer polymerisation technology (RAFT) to expand upon its high-end polymer development capabilities for the biotech industry.
Mirus Bio Vice President of Scientific Operations Scott Hayes said the agreement would allow the company to broaden its expertise.
"This agreement with CSIRO broadens the scope of specialised polymer design tools available to Mirus and facilitates our continued efforts to improve nucleic acid transfer capabilities. We expect that utilization of RAFT will lead to new discoveries and expedite our product development efforts," Dr Hayes said.
"CSIRO is very pleased to be working with Mirus Bio in the transfection space," said Cathy Foley from CSIRO.
"The scientists at Mirus are leaders in introducing innovative products in this area and have developed a range of delivery technologies for researchers in the biotech industry that can make use of our polymer technology," she said.
"RAFT has very broad applicability in the biotech and biomedical industry because of the need for new and improved multifunctional polymers for many different applications. RAFT enables the rapid, rational design and prove-out of bespoke macromolecules," Dr Foley said.